Cargando…

Neutralization of SARS-CoV-2 lineage B.1.1.7 pseudovirus by BNT162b2 vaccine–elicited human sera

Recently, a new severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) lineage called B.1.1.7 (variant of concern: VOC 202012/01), which is reported to spread more efficiently and faster than other strains, emerged in the United Kingdom. This variant has an unusually large number of mutations,...

Descripción completa

Detalles Bibliográficos
Autores principales:	Muik, Alexander, Wallisch, Ann-Kathrin, Sänger, Bianca, Swanson, Kena A., Mühl, Julia, Chen, Wei, Cai, Hui, Maurus, Daniel, Sarkar, Ritu, Türeci, Özlem, Dormitzer, Philip R., Şahin, Uğur
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Association for the Advancement of Science 2021
Materias:	Reports
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7971771/ https://www.ncbi.nlm.nih.gov/pubmed/33514629 http://dx.doi.org/10.1126/science.abg6105

Ejemplares similares

Neutralization of SARS-CoV-2 Omicron by BNT162b2 mRNA vaccine–elicited human sera
por: Muik, Alexander, et al.
Publicado: (2022)

Neutralizing Activity of BNT162b2-Elicited Serum
por: Liu, Yang, et al.
Publicado: (2021)

Neutralization of N501Y mutant SARS-CoV-2 by BNT162b2 vaccine-elicited sera
por: Shi, Pei-Yong, et al.
Publicado: (2021)

Neutralization of N501Y mutant SARS-CoV-2 by BNT162b2 vaccine-elicited sera
por: Xie, Xuping, et al.
Publicado: (2021)

BNT162b2-Elicited Neutralization against New SARS-CoV-2 Spike Variants
por: Liu, Yang, et al.
Publicado: (2021)

BNT162b2-elicited neutralization of Delta plus, Lambda, Mu, B.1.1.519, and Theta SARS-CoV-2 variants
por: Liu, Jianying, et al.
Publicado: (2022)

SARS-CoV-2 Neutralization with BNT162b2 Vaccine Dose 3
por: Falsey, Ann R., et al.
Publicado: (2021)

Safety, Immunogenicity, and Efficacy of the BNT162b2 Covid-19 Vaccine in Adolescents
por: Frenck, Robert W., et al.
Publicado: (2021)

Neutralization of SARS-CoV-2 spike 69/70 deletion, E484K, and N501Y variants by BNT162b2 vaccine-elicited sera
por: Xie, Xuping, et al.
Publicado: (2021)

Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine
por: Polack, Fernando P., et al.
Publicado: (2020)

Safety and Immunogenicity of the BNT162b2 Vaccine Coadministered with Seasonal Inactivated Influenza Vaccine in Adults
por: Murdoch, Louise, et al.
Publicado: (2023)

The effect of SARS-CoV-2 D614G mutation on BNT162b2 vaccine-elicited neutralization
por: Zou, Jing, et al.
Publicado: (2021)

Safety and Efficacy of a Third Dose of BNT162b2 Covid-19 Vaccine
por: Moreira, Edson D., et al.
Publicado: (2022)

Neutralization of Omicron sublineages and Deltacron SARS-CoV-2 by three doses of BNT162b2 vaccine or BA.1 infection
por: Kurhade, Chaitanya, et al.
Publicado: (2022)

Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine through 6 Months
por: Thomas, Stephen J., et al.
Publicado: (2021)

A randomized study to evaluate safety and immunogenicity of the BNT162b2 COVID-19 vaccine in healthy Japanese adults
por: Haranaka, Miwa, et al.
Publicado: (2021)

Neutralization and durability of 2 or 3 doses of the BNT162b2 vaccine against Omicron SARS-CoV-2
por: Xia, Hongjie, et al.
Publicado: (2022)

Evaluation of the BNT162b2 Covid-19 Vaccine in Children 5 to 11 Years of Age
por: Walter, Emmanuel B., et al.
Publicado: (2021)

Neutralization of Omicron BA.1, BA.2, and BA.3 SARS-CoV-2 by 3 doses of BNT162b2 vaccine
por: Kurhade, Chaitanya, et al.
Publicado: (2022)

Bivalent Omicron BA.1–Adapted BNT162b2 Booster in Adults Older than 55 Years
por: Winokur, Patricia, et al.
Publicado: (2023)

Effectiveness of the BNT162b2 Covid-19 Vaccine against the B.1.1.7 and B.1.351 Variants
por: Abu-Raddad, Laith J., et al.
Publicado: (2021)

Evaluation of BNT162b2 Covid-19 Vaccine in Children Younger than 5 Years of Age
por: Muñoz, Flor M., et al.
Publicado: (2023)

Immunogenicity and Safety of a Third COVID-19 BNT162b2 mRNA Vaccine Dose in 5- to 11-Year Olds
por: Simões, Eric A F, et al.
Publicado: (2023)

Immunogenicity and safety of BNT162b2 mRNA vaccine in Chinese adults: A phase 2 randomised clinical trial
por: Hui, Ai-Min, et al.
Publicado: (2022)

Transmission of SARS-CoV-2 Alpha Variant (B.1.1.7) From a BNT162b2-Vaccinated Individual
por: Kernéis, Solen, et al.
Publicado: (2021)

Influence of a Heterologous (ChAdOx1-nCoV-19/BNT162b2) or Homologous (BNT162b2/BNT162b2) Vaccination Regimen on the Antibody and T Cell Response to a Third Vaccination with BNT162b2
por: Reiter, Rieke, et al.
Publicado: (2022)

Reduced neutralization of SARS-CoV-2 Omicron variant by BNT162b2 vaccinees’ sera: a preliminary evaluation
por: Mileto, D., et al.
Publicado: (2022)

Effectiveness of BNT162b2 vaccine against the B.1.1.7 variant of SARS-CoV-2 among healthcare workers in Brescia, Italy.
por: Sansone, E., et al.
Publicado: (2021)

Serosurvey in BNT162b2 vaccine-elicited neutralizing antibodies against authentic B.1, B.1.1.7, B.1.351, B.1.525 and P.1 SARS-CoV-2 variants
por: Zani, Alberto, et al.
Publicado: (2021)

BNT162b2 vaccination effectively prevents the rapid rise of SARS-CoV-2 variant B.1.1.7 in high-risk populations in Israel
por: Munitz, Ariel, et al.
Publicado: (2021)

BNT162b2 vaccine for prevention of COVID-19
Publicado: (2021)

Boosting BNT162b2 vaccine efficacy in CLL
por: Bhat, Seema A., et al.
Publicado: (2022)

Erythema Multiforme after BNT162b2 Vaccination
por: Katayama, Sho, et al.
Publicado: (2022)

Pseudo-Anaphylactic Reactions to Pfizer BNT162b2 Vaccine: Report of 3 Cases of Anaphylaxis Post Pfizer BNT162b2 Vaccination
por: Lim, Xin Rong, et al.
Publicado: (2021)

Immune Persistence and Safety After SARS-CoV-2 BNT162b1 mRNA Vaccination in Chinese Adults: A Randomized, Placebo-Controlled, Double-Blind Phase 1 Trial
por: Li, Jingxin, et al.
Publicado: (2022)

Longitudinal Analysis of SARS-CoV-2-Specific Cellular and Humoral Immune Responses and Breakthrough Infection following BNT162b2/BNT162b2/BNT162b2 and ChAdOx1/ChAdOx1/BNT162b2 Vaccination: A Prospective Cohort in Naive Healthcare Workers
por: Ko, Geon Young, et al.
Publicado: (2023)

A heterologous AZD1222 priming and BNT162b2 boosting regimen more efficiently elicits neutralizing antibodies, but not memory T cells, than the homologous BNT162b2 regimen
por: Baek, Yae Jee, et al.
Publicado: (2023)

Efficacy and safety of the BNT162b2 mRNA COVID-19 vaccine in participants with a history of cancer: subgroup analysis of a global phase 3 randomized clinical trial
por: Thomas, Stephen J., et al.
Publicado: (2022)

mRNA-Based Vaccine BNT162b2 Might Reduce Severe Acute Respiratory Syndrome Coronavirus 2 B.1.1.7 Variant Transmission in Japanese Population
por: Matsunaga, Takuya, et al.
Publicado: (2021)

BNT-162b1: Stevens-Johnson syndrome: case report
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_quq5tedkcr34dj3tqk7dl752o1